How Analysts Feel About Bristol-Myers Squibb Company (BMY)?

As of Thursday close, Bristol-Myers Squibb Company’s (NYSE:BMY) stock was up $0.15, moving up 0.20 percent to $76.30. The average number of shares traded per day over the past five days has been 15,910,880 shares. 3 times new highs have been achieved over the past 5 days, with a $0.05 gain in that time frame. In the last twenty days, the average volume was 15,664,515, while in the previous 50 days, it was 15,527,722.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .


Since last month, BMY stock retreated -0.33%. Shares of the company fell to $73.35 on 04/29/22, the lowest level in the past month. A 52-week high of $78.17 was reached on 04/21/22 after having rallying from a 52-week low of $53.22. Since the beginning of this year, BMY’s stock price has risen by 22.37% or $13.95, and marked a new high 28 times. However, the stock has declined by -2.39% since its 52-week high.

Bristol-Myers Squibb Company (BMY) last reported insider trading activity 53 days ago on Mar 21. Caforio Giovanni, the Board Chair and CEO of the company, disposed of 25,000 shares for $71.52 on Mar 21. It resulted in a $1,788,000 divestment by the insider. VESSEY RUPERT sold 74,559 shares at an average price of $69.25 on Mar 16. The insider now owns 46,308 shares following the transaction. On Mar 14, SVP & Controller Santiago Karen Murphy sold 6,577 shares at $69.19 apiece. The transaction was valued at $455,096.

Valuation Metrics

Right now, Bristol-Myers Squibb Company (BMY) has a P/E ratio of about 27.10. The stock’s beta is 0.48. Besides these, the trailing price-to-sales (P/S) ratio of 3.44, the price-to-book (PB) ratio of 5.18, and the price-to-cash flow ratio of 15.14 may also be considered.

The latest dividend of $0.54 per share was paid out, remained unchanged from last year’s $0.54. On Monday December 13 2021, a $0.05 dividend increase was announced.

Financial Health

In the three months ended September 29, Bristol-Myers Squibb Company’s quick ratio stood at 1.20, while its current ratio was 1.30, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending September 29 was 1.19, and the total debt-to-equity ratio was 1.42. On the profitability front, the trailing twelve-month gross margin is 79.60% percent. In the year ended September 29, operating margins totaled 19.00%. Based on annual data, BMY earned $36.45 billion in gross profit and brought in $46.38 billion in revenue.

A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 9.40%. Return on equity (ROE) for the past 12 months was 17.70%.

In Bristol-Myers Squibb Company’s quarter-end financial report for September 29, it reported total debt of $37.45 billion against cash and short-term investments of $2.6 billion. According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. BMY’s revenue rose 4.94% to $11.98 billion during the quarter, while net income inched up to $11.65 billion. While analysts expected Bristol-Myers Squibb Company to report $1.92 quarterly earnings, the actual figure was $2 per share, beating the consensus estimate by 4.20%. During the quarter, the company generated $4.27 billion in EBITDA. The liabilities of Bristol-Myers Squibb Company were 71.39 billion at the end of its most recent quarter ended September 29, and its total debt was $45.6 billion. The value of shareholders’ equity is $2.13 billion.

Technical Picture

This quick technical analysis looks at Bristol-Myers Squibb Company’s (BMY) price momentum. With a historical volatility rate of 9.51%, the RSI 9-day stood at 53.74% on 12 May.

With respect to its five-day moving average, the current Bristol-Myers Squibb Company price is up by +0.07% percent or $0.05. At present, BMY shares trade -0.74% below its 20-day simple moving average and +23.94% percent above its 100-day simple moving average. However, the stock is currently trading approximately +10.82% above its SMA50 and +11.01% above its SMA200.

Stochastic coefficient K was 63.94% and Stochastic coefficient D was 63.06%, while ATR was 1.61. Given the Stochastic reading of 67.12% for the 14-day period, the RSI (14) reading has been calculated as 55.91%. As of today, the MACD Oscillator reading stands at 0.21, while the 14-day reading stands at 0.23.

Analyst Ratings

Bristol-Myers Squibb Company (BMY) has been rated Overweight by analysts. According to 1 brokerage firm, BMY is a sell, and 7 firms recommend it is a Hold. There are 2 analysts who say the stock is underweight. A total of 2 analysts rate Bristol-Myers Squibb Company stock as buy, with 11 recommending it as overweight.

With a median target price of $80.00, the current consensus forecast for the stock is $63.00 – $94.00. Based on these forecasts, analysts predict Bristol-Myers Squibb Company (BMY) will achieve an average price target of $78.50.


Please enter your comment!
Please enter your name here

Hot Topics

Related Articles